Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study)
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To study the antineoplastic effect of the investigational drug.
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals
Japan: Ministry of Health, Labor and Welfare
CSTI571B1202
NCT00237172
September 2002
Name | Location |
---|